Riskpilot← Back to searchSign inGet full accessD3-Pharmacy Aps
APSActiveCVR 71087611Vesterhedenvej 64Wholesale of pharmaceutical and medical goods · NACE 4646Est. 1982— employeeswww.d3pharmacy.dk
Revenue 2024
DKK -12K
+12% vs 2023
EBITDA margin
100.0%
-105% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
DKK -13K
-135% vs 2023
| Revenue | DKK -12K | +12% |
| EBITDA | DKK -12K | -105% |
| Net profit | DKK -13K | -135% |
| Total assets | DKK 530K | -3% |
| Equity | DKK 530K | -2% |
| Employees | — | — |
Legal name
D3-Pharmacy Aps
CVR number
71087611
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
26. maj 1982
Share capital
DKK 100.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er handel og investering og dermed beslægtet virksomhed.
Address
Vesterhedenvej 64
Phone
+4530324840
Email
info@d3pharmacy.dk
Website
www.d3pharmacy.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.174 | 117 | 189 | 107 | 192 | 236 | -7 | -8 | -8 | -3 | -10 | -11 | -12 |
| Staff expenses | -0 | -0 | -5 | -5 | -5 | -5 | -5 | -7 | -5 | -5 | -5 | -5 | -0 |
| EBITDA | -1.174 | 117 | 184 | 102 | 187 | 231 | -12 | -15 | -13 | -8 | -15 | -6 | -12 |
| Depreciation & amort. | -21 | -18 | -15 | -4 | -3 | -374 | -0 | -0 | -2 | -2 | -3 | -2 | -2 |
| EBIT | -1.194 | 99 | 169 | 98 | 184 | -143 | -12 | -15 | -15 | -10 | -18 | -8 | -15 |
| Net financials | 3 | -54 | -17 | -6 | -0 | -6 | -0 | -3 | -2 | 0 | -5 | 1 | -2 |
| Profit before tax | -1.192 | 45 | 152 | 92 | 184 | -149 | -12 | -18 | -17 | -10 | -23 | -7 | -17 |
| Tax | -294 | 13 | 48 | 27 | 54 | -33 | -2 | -4 | -3 | -3 | -5 | -2 | -4 |
| Net profit | -898 | 32 | 104 | 65 | 130 | -116 | -11 | -14 | -14 | -7 | -18 | -6 | -13 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.098 | 1.455 | 1.412 | 1.219 | 1.259 | 1.361 | 1.357 | 593 | 590 | 1.187 | 1.040 | 546 | 530 |
| Equity | 496 | 528 | 632 | 697 | 727 | 611 | 600 | 588 | 574 | 567 | 549 | 543 | 530 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 602 | 928 | 780 | 522 | 531 | 750 | 757 | 5 | 16 | 621 | 491 | 2 | 0 |
| Total debt | 602 | 928 | 780 | 522 | 531 | 750 | 757 | 5 | 16 | 621 | 491 | 2 | 0 |
EBITDA margin
-1231000.0%
This company
15.8%
Market median
-7791239% vs market
20122024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20122024
Return on equity
-2.5%
This company
18.4%
Market median
-114% vs market
20122024
Net profit margin
-1313500.0%
This company
8.1%
Market median
-16216149% vs market
20122024
Asset turnover
-0.02×
This company
1.12×
Market median
-102% vs market
20122024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
FH Audit | Audit | 1982 | — | — |
HM Management | Management | 1982 | — | — |
AJ Management | Management | 1982 | — | — |
FS Management | Management | 1982 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1982 | — | — | |
| Board of Directors | 1982 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 1982 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
D3-Pharmacy Aps 
Juni Cafe ApSBoard members of D3-Pharmacy Aps also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Finn Harlis | Audit | 0 companies |
| Hanne-Mette Marie Johansen Jensen | Management | 0 companies |
| Arly Jensen | Management | 0 companies |
| Freya Selena Petersen | Management | 0 companies |
| Poul Erik Kjeldgaard | Board of Directors | 0 companies |
| Henri Frank Müntzberg | Board of Directors | 0 companies |